Overall, the authors concluded that clinical trials are a viable option for patients. For patients with advanced or recurrent disease and no active life-threatening illnesses, there were no differences in survival or duration of survival within the three treatment groups—surgery alone, surgery with adjuvant chemotherapy, or surgery + adjuvant chemotherapy.
The exact cause of gynecologic cancer is unknown. Factors that correlate with the development thereof are: age at the time of diagnosis, female breast feeding, estrogen receptor status, estrogen-producing cancers, cervical lesions, uterine leiomyoma, and pregnancy. Smoking seems to be linked to many of these associations.
Many patients with gynecologic cancers will live long and active lives despite disease progression, and, in some cases, the disease is still in remission at the time of the survey.
Clinicians are faced with a difficult decision between chemotherapy and radiotherapy: two main treatments for gynecologic cancers. Although radiotherapy is generally a first-line treatment, it is often delayed so that chemotherapy is administered. Clinical trials may be the fastest way to tell us the value of chemotherapy plus radiotherapy. This review of available data has revealed that radiotherapy was commonly used before chemotherapy; it was also indicated that the results of most published research supports the effectiveness of radiotherapy alone; chemotherapy plus systemic treatment is now preferred in almost all trials; chemotherapy is preferable at least to radiotherapy in combination with surgery; chemotherapy plus local radiotherapy is considered a reasonable first-line treatment.
The most common signs of gynecologic cancers are pain with urination, unexplained weight loss, and vaginal bleeding or discharge. The most unusual sign of cancer is an enlarged, firm thigh mass, which, if found in women as young as 20 years of age, is more likely to be a type of cancer.
Although this patient population is at a higher risk for developing [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer), the 5-year survival for patients with benign ovarian neoplasms is high compared with that of patients with malignant gynecologic neoplasms. The current treatments are optimized before and after surgery, and they decrease morbidity and mortality regardless of the histologic subtype and stage of the cancers. If patients can choose a course of care that emphasizes the most effective approach, the prognosis is improved; however, the optimal treatment approach is undefined.
Approximately 5,250 women (0.8%) and 15,250 men (2.5%) will be diagnosed with primary or metastatic [uterine cancer](https://www.withpower.com/clinical-trials/uterine-cancer)s annually, accounting for about 12.7 million total new cancer cases, of which 4.7 million will be females.
Recent findings refute the conclusion that tumour tissue donation increases the rate of tumour recurrence when compared to a placebo in women having a total radical hysterectomy for gynaecological cancer. This trial was registered with www.controlled-trials.com (CRT Number: ISRCTN 60920861).
Tissue collection continues to expand and now include most tumour types. It seems the future may see increased use of ex-vivo tissue and other advanced regenerative technologies to develop a Tissue Procurement Unit as a key component of any cancer centre.
Recent studies have been reported. Research for targeting therapeutic agents is underway; specifically, clinical trials are designed for [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer), cervical cancer, and uterine leiomyoma, which are commonly diagnosed in the United States. In addition to studies that target individual cancers, studies have also been conducted to identify the specific role of the microenvironment in these cancers; these findings will enable future therapeutics that use more personalized treatments.
Collected tumour tissue samples should be used for research only if a high level of confidence in the results can be assured. Therefore, the use of metastatic tumours should be avoided.
[Gonorrhea infections are most commonly seen in women between the ages of 10-30 years of age. And more than half of the cases will heal, but symptoms reappear. After 1 year, gonorrhea reappears in 8 of 29 cases (27%) and 15.5 years on average, and the most common symptoms were: itching, pain, irritation during sexual activity, and bleeding. A new set of symptoms appear when the disease recurs for about 1-to-2 years.